Ask your AI about any drug, trial or company

Add OpenLandscape to the AI app you already use, once. Every answer links to its source.

Your AI assistant

  1. 1Copy the setup prompt
  2. 2Paste it into your AI assistant

    It sets itself up, or tells you the two clicks to make. Works with:

    ClaudeChatGPTCursorClaude CodeGemini CLIany other
  3. 3Sign in, click Allow, then ask
    Map every amylin drug in Phase 2 or later, with next milestones.

Or add it from the app's directory: Claude ↗

Server URLFor adding it by hand
https://openlandscape.app/mcp

Your app asks you to sign in once. Free, no payment card needed.

What it can do

Your app picks these by itself. Ask in plain words; these are examples.

landscape
Every drug in a disease, target or company, with stage and next milestone.“Map every amylin drug in Phase 2 or later.”
catalysts
Readouts and regulator decisions due in the next weeks.“Which oral GLP-1s read out in the next six months?”
trials
Trials by drug, company, phase, country or date, each linked to its registry record.“List Phase 3 obesity trials running in China.”
drug
Everything about one drug: names, company, stage, approvals, dates and trials.“Tell me everything about mazdutide.”
changes
What changed this week in the landscapes, drugs and companies you follow.“What changed in what I follow this week?”
search
Finds a drug or company under any of its names, codes or brand names.“What is HRS9531?”
who_runs_trials
Companies and trial sites ranked by how many active trials they run.“Who runs the most lung cancer trials in Europe?”

A real answer

claude · openlandscape · live data
› which oral GLP-1 pills are in phase 3 or later, and who reads out first?

● openlandscape.landscape(area: "oral GLP-1", phase_min: 3)
drugcompanyphasenext
orforglipronEli LillyApproved (US)Feb 2027
HRS-7535HengruiFiled (China)Dec 2026
HDM1002Huadong MedicinePhase 316 Feb 2027
MDR-001MindRank AIPhase 3Jun 2027
VK2735VikingPhase 31 Jul 2027
DA-302168SChengdu DIAOPhase 39 Jul 2027
elecoglipronAstraZenecaPhase 36 Apr 2028
ASC30AscletisPhase 3Jul 2028
aleniglipronStructure TherapeuticsPhase 3Sep 2028

9 drugs in Phase 3 or later, across 58 active trials. The first registry date is HRS-7535 (Hengrui · Kailera), Dec 2026, NCT06820099.

✓ 9 drugs · 58 trials · sources attached